| 000 | 01695 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513143432.0 | ||
| 264 | 0 | _c19980616 | |
| 008 | 199806s 0 0 eng d | ||
| 022 | _a0012-1797 | ||
| 024 | 7 |
_a10.2337/diabetes.47.6.945 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChakravarthy, U | |
| 245 | 0 | 0 |
_aConstitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. _h[electronic resource] |
| 260 |
_bDiabetes _cJun 1998 |
||
| 300 |
_a945-52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBlotting, Northern |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 | _aCalibration |
| 650 | 0 | 4 | _aCattle |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xcytology |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aGene Expression Regulation, Enzymologic _xdrug effects |
| 650 | 0 | 4 |
_aGlucose _xpharmacology |
| 650 | 0 | 4 |
_aGlycation End Products, Advanced _xpharmacology |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 | _aMicrocirculation |
| 650 | 0 | 4 |
_aNitric Oxide Synthase _xbiosynthesis |
| 650 | 0 | 4 | _aNitric Oxide Synthase Type III |
| 650 | 0 | 4 |
_aNitrites _xmetabolism |
| 650 | 0 | 4 |
_aPolarography _xmethods |
| 650 | 0 | 4 |
_aProtein Kinase C _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRetinal Vessels |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aHayes, R G | |
| 700 | 1 | _aStitt, A W | |
| 700 | 1 | _aMcAuley, E | |
| 700 | 1 | _aArcher, D B | |
| 773 | 0 |
_tDiabetes _gvol. 47 _gno. 6 _gp. 945-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/diabetes.47.6.945 _zAvailable from publisher's website |
| 999 |
_c9571568 _d9571568 |
||